Affinity Asset Advisors, LLC Protagonist Therapeutics, Inc Transaction History

Affinity Asset Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$21.79 - $32.15 $2.18 Million - $3.22 Million	100,000 New	100,000 $2.89 Million
Q2 2022 Aug 12, 2022	SELL	$7.06 - $25.52 $2.12 Million - $7.66 Million	-300,000 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$23.34 - $36.08 $1.37 Million - $2.12 Million	58,881 Added 24.42%	300,000 $7.1 Million
Q4 2021 Feb 11, 2022	BUY	$17.63 - $37.1 $4.25 Million - $8.95 Million	241,119 New	241,119 $8.25 Million
Q3 2021 Nov 12, 2021	SELL	$12.95 - $49.69 $1.81 Million - $6.96 Million	-140,100 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$25.57 - $44.88 $2.3 Million - $4.04 Million	90,100 Added 180.2%	140,100 $6.29 Million
Q1 2021 May 14, 2021	BUY	$19.02 - $31.15 $951,000 - $1.56 Million	50,000 New	50,000 $1.3 Million

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.99B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.